Navigation Links
Texas Cardiac Arrhythmia Institute at St. David's Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation

AUSTIN, Texas, Oct. 7 /PRNewswire/ -- The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center has been selected as one of only a few sites in the nation to participate in an FDA-approved clinical trial for a new device to treat persistent atrial fibrillation. TCAI, an international treatment, training and research center specializing in heart rhythm disorders, is a partnership between St. David's Medical Center and Texas Cardiovascular Consultants.

"This is just another example of how TCAI is leading the nation in pioneering new treatments for atrial fibrillation," Dr. Rodney Horton, electrophysiologist, Texas Cardiac Arrhythmia, said. "We are proud to take part in this study that has the potential to greatly enhance the future treatment of A Fib."

Heart arrhythmias are very common, affecting more than two million people nationwide. Atrial fibrillation, or A Fib, is the most common heart arrhythmia. A Fib is a rhythm disorder that affects the electrical system, or "wiring," of the heart muscle. It is often treated with cardiac ablation -- a procedure that allows physicians to deliver energy directly to the heart muscle at precise points that trigger the arrhythmia, creating a lesion that blocks the pathway for the abnormal heart rhythm. The new study involves second generation software (Gen II) that uses a catheter believed to result in the formation of a more effective lesion.

"In the Gen II study, we are evaluating a revolutionary radiofrequency ablation catheter," Dr. Horton said. "This device is able to monitor the temperature at its tip, giving electrophysiologists the ability to better control the delivery of energy through the catheter and generate a more effective lesion." In traditional cardiac ablation, room temperature saline is injected through the catheter prior to the delivery of energy. Because standard catheters do not measure the temperature at the catheter's tip, overheating may occur, resulting in the generation of a less effective lesion.

"While many studies involve less complex cases, we were particularly interested in this one because participants must experience more severe atrial fibrillation," Horton said. "The study incorporates the technology that we already know is effective and advances it to an even higher level, helping us generate a consistently effective lesion in highly complicated cases."

The study is designed for patients who have persistent A Fib. Participants must also meet other specific criteria. To inquire about participation in the clinical trail, please call 512-544-2342.

Texas Cardiac Arrhythmia

Texas Cardiac Arrhythmia, a division of Texas Cardiovascular Consultants, was founded in 1996 by Rodney Horton, M.D. The practice has grown to include nine clinical electrophysiologists specializing in the area of heart rhythm disturbances. Texas Cardiac Arrhythmia Research, a division of Texas Cardiovascular Consultants, is committed to providing opportunities for patients in Central Texas to participate in studies utilizing the latest technology in the area of cardiac electrophysiology.

St. David's Medical Center

Since 1924, St. David's Medical Center has provided quality medical care to the residents of Central Texas. Conveniently located in central Austin at 32nd Street and IH-35, St. David's Medical Center provides comprehensive care with special expertise in neurology and neurosurgery, cardiac services, bariatric surgery, orthopedics, maternity and newborn services and rehabilitation. The medical center includes St. David's Hospital (acute care) and St. David's Rehabilitation Center (physical medicine and rehabilitation). For more information, please visit

Media Contacts:

Erin Ochoa and Kristin Marcum

Elizabeth Christian & Associates Public Relations


SOURCE The Texas Cardiac Arrhythmia Institute at St. David?sMedical Center
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Vical Receives NIH Grant for an Immunotherapeutic Herpes DNA Vaccine; Herpes Experts at University of Washington and University of Texas to Conduct Preclinical Development
2. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
3. Caliper Life Sciences Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
4. Personalized Medicine - The Genomic Revolution in Cardiac Care
5. FAU Receives Patent for Invention Which Induces and Restores Cardiac Muscle Function
6. Signalife Completes Testing of Modules for Holter and Intra-Cardiac Monitor
7. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
8. Study Shows Vernakalant Hydrochloride is Effective in Conversion to Normal Heart Rhythm in Atrial Fibrillation Patients Following Cardiac Surgery
9. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
10. Do-It-Yourself Cardiac Bypass Surgery: All You Need is Walking Shoes
11. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
Post Your Comments:
(Date:6/24/2016)... Mass. , June 24, 2016   ... Spaulding Rehabilitation Network,s Dean Center for Tick ... Physical Medicine and Rehabilitation, MIT Hacking Medicine, University ... for Innovation, today announced the five finalists of ... for Lyme disease.  More than 100 scientists, clinicians, ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/26/2016)... PLAINSBORO, N.J. (PRWEB) , ... June 27, 2016 , ... ... same sources, yet in many ways they remain in the eye of the beholder, ... Oncology (EBO), a publication of The American Journal of Managed Care. For the full ...
(Date:6/26/2016)... ... 26, 2016 , ... PawPaws brand pet supplements owned by Whole ... enhance the health of felines. The formula is all-natural and is made from Chinese ... PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
Breaking Medicine News(10 mins):